Jing Tong
About Jing Tong
Jing Tong is a Senior Scientist at Bristol-Myers Squibb and Director at Shanghai Junshi Biosciences Co., Ltd., with extensive experience in biotherapeutics and regulatory submissions.
Current Professional Roles
Jing Tong currently holds dual professional roles in the biopharmaceutical sector. She is the Director at Shanghai Junshi Biosciences Co., Ltd. based in Suzhou, Jiangsu, China, and serves as a Senior Scientist at Bristol-Myers Squibb in the Greater Boston Area. Both positions highlight her extensive expertise in the field of biotherapeutics.
Previous Work Experience
Before her current roles, Jing Tong gained significant experience in various esteemed organizations. She worked as a Senior Scientist at PPD from 2013 to 2014 in Middleton, Wisconsin. Prior to that, she was a Co-op at Johnson & Johnson from 2012 to 2013 in the Greater Philadelphia Area. Moreover, she spent five years as a Ph.D. student at the University of Nebraska Medical Center from 2008 to 2013 in Greater Omaha Area.
Educational Background
Jing Tong's educational qualifications include a Ph.D. in Pharmaceutical Sciences from the University of Nebraska Medical Center, where she studied from 2008 to 2013. Prior to that, she earned a B.S. in Life Sciences from the University of Science and Technology of China, completing her studies from 2004 to 2008. Her academic background laid the foundation for her expertise in biotherapeutics.
Expertise in Injectable Biotherapeutics
Jing Tong has extensive experience in the development and characterization of injectable biotherapeutics, particularly monoclonal antibodies. Her work involves managing internal and external analytical and characterization activities, including method development, qualification, and transfer. She also leads technical investigations on analytical testing issues, such as Out of Specification (OOS) and Out of Trend (OOT) results.
Regulatory Submission Contributions
In her professional capacity, Jing Tong develops drug substance and drug product specifications for regulatory submissions. She authors, edits, and reviews sections for documents related to submissions like Investigational New Drug (IND) and Clinical Trial Application (CTA). Additionally, she is responsible for responding to regulatory questions, showcasing her comprehensive involvement in regulatory affairs.